VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	8/6/2013 5:05:46 PM
	of 23519

A<span class="articleLocation">ug 6 (Reuters) - Sales of Vivus Inc's obesity pill fell far short of analysts' estimates for the second quarter, indicating that new CEO Anthony Zook faces the daunting task of boosting uptake of the first weight-loss drug to be launched in more than a decade. April-June net product revenue, reflecting sales of the diet drug Qsymia, was $5.5 million, compared with $4.1 million in the quarter ended March. This was well below analysts' average estimate of $12.8 million, according to Thomson Reuters I/B/E/S. Net loss widened to $55.5 million, or 55 cents per share, from $24.0 million, or 24 cents per share, a year earlier. Analysts had expected a loss of 44 cents per share.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next